27
Mar

Pfizer says the Phase IIb study for its closely-watched PCSK9 cholesterol drug bococizumab (RN316) scored the primary endpoint on all doses, which should help steer a massive Phase III program that started out last fall with 22,000 patients.

…read more

Source: Pfizer says PCSK9 study was a winner, boosting its chances in hectic R&D race

    

0 No comments